{
    "nct_id": "NCT05819853",
    "official_title": "Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome",
    "inclusion_criteria": "Healthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 12 Years\nMust have maximum age of 35 Years",
    "exclusion_criteria": "1. Diagnosed with or have a family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Family history of medullary thyroid cancer or thyroid nodule palpated by endocrinologist at screening. - Per approved drug label\n2. Use of medications known to affect insulin sensitivity: metformin (cannot have been used in the 3 months prior to screening for the untreated arm of the study), chronic oral steroids, oral glucocorticoids within 10 days, atypical antipsychotics, immunosuppressant agents, HIV medications, estrogen-containing hormonal contraception (cannot have been used in the 6 months prior to screening), progesterone-containing hormonal contraception (cannot have been used in the 3 months prior to screening). Dermal patch or vaginal ring contraception methods. Weight loss medications or stimulants. Use of other products containing other GLP-1 agonists.\n3. Weight loss medications in the last 6 months\n4. Currently pregnant or breastfeeding women. Development of pregnancy during the study period will necessitate withdrawal from the study.\n5. Severe illness requiring hospitalization within 60 days.\n6. Diabetes, defined as Hemoglobin A1C ≥6.5%\n7. Anemia, defined as Hemoglobin < 12 mg/dL\n8. Diagnosed major psychiatric or developmental disorder limiting informed consent.\n\n10) Known liver disease other than NAFLD, or AST or ALT >125 IU/L. 11) Personal history of pancreatitis 12) Known renal disease of any severity or an eGFR at screening of <45ml/min/1.73m2 13) History of severe GI disease (e.g., gastroparesis) 14) History of gallstones 15) Untreated thyroid disease 16) History of hypersensitivity to semaglutide 17) Other causes of hyperandrogenism (example: tumor, CAH) or amenorrhea (untreated thyroid disease, tumor, primary ovarian failure, prolactinoma).\n\n18) Active symptoms or undergoing treatment for anorexia nervosa or binging/purging disorder 19) Desiring pregnancy in the next 12-18 months. 20) Bariatric surgery 21) Use of THC (smoking or edible) more than 3 days a week 22) Alcohol use-drinking more than 2 drinks, more than 3 days a week 23) Any potential participants who cannot/will not commit to abstinence, use of a copper intrauterine device (IUD), or use of double barrier forms of contraception.",
    "miscellaneous_criteria": "Inclusion Criteria\n\n1. Female\n2. Ages 12-35 years\n3. Sedentary- less than 2 hours of moderate (jogging, swimming etc.) exercise a week.\n4. Oligomenorrhea, on or off metformin, as defined per age category in the most recent 2018 PCOS international guidelines\n5. Initial BMI based on age and weight:\n\n   1. If <18 years, initial BMI percentile ≥95\n   2. If 18-35 years, initial BMI ≥30 kg/m2 OR initial BMI ≥27 kg/m2 with at least one weight-related comorbid condition, e.g., hypertension or dyslipidemia\n   3. Must be weight stable within ±5kg in the 3 months prior to enrollment\n6. Diagnosed with PCOS per the most stringent NIH criteria with adaptation for adolescents (oligomenorrhea >24 months post-menarche or primary amenorrhea after age 15 years and clinical/ biochemical hypertestosteronemia\n7. Participants cannot be on hormonal contraception, so participants should remain abstinent or use reliable non-hormonal contraception (e.g., copper IUD) for the entire study period. For participants who receive semaglutide, they should avoid pregnancy for at least 2 months after stopping medication to avoid fetal exposure to the medication.\n8. For participants in the metformin + semaglutide group, participants must have been stable on ≥ 1500 mg of metformin a day for at least 3 months by time of screening"
}